



30th October 2015

Ms. Usha Sharma,
Deputy General Manager,
Surveillance and Supervision,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI – 400 001

Dear Madam,

Re.: Clarification/Confirmation on news item appearing in “CNBC TV 18”

We refer to your letter no. L/DOSS/ONL/RV/RD/2015-16/144 and email of 29th October 2015 and our interim reply,

We wish to clarify that our Company, Sanofi India Limited whose shares are listed on your Exchange, had not entered into any negotiations for development of vatelizumab molecule.

Our parent company, Sanofi SA has announced , in a press release issued from Paris, France yesterday on its Q 3 2015 results, that it would not pursue development of the molecule. Copy of the press release issued by Sanofi SA is enclosed for your ready reference. Please see 1st para on page 11 of the Press Release.

Thanking you,

Yours faithfully,
SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to read "K. Subramani".

K.SUBRAMANI
COMPANY SECRETARY

Encl.: a/a